Loading presentation...

Present Remotely

Send the link below via email or IM


Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.


MMJ Program Summary

No description

Daniel Ryszka

on 14 September 2016

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of MMJ Program Summary

Thank You!
NYS Medical Marijuana Program

Lisa Valle MS, Ed.
Jeffrey Lombardo, PharmD., BCOP
Daniel Ryszka RPh.

And….so that patient's should NEVER have to suffer!
Cost of the medications: not covered by insurance ($300-1,200/month)

Locations: 20 throughout all NYS. Bad weather? Shortages? Patients are driving up to 8 hours round trip

Variable Strains: 5 companies each producing “their” brand, not all are open, and have a full line of products

The registered organizations are not providing the patients with a comprehensive strain profile for the product they are receiving

Limited qualifying conditions

Not enough providers: Approximately 90,000 doctors in NYS. As of 5/9/16 only 564 are registered providers for a population of 80 million people living in NYS

Hospital admission: Need clear guidance from the DOH regarding handling procedures

Schools: Need guidance from the DOH regarding safehandling of product if a dose is required in school

Lack of transparency from the DOH
Concerns and Issues
Where will the Registered Organizations and Dispensing Facilities be located?
Allow states to legalize marijuana for medical use without federal interference

Permit interstate commerce in cannabidiol (CBD) oils

Reschedule marijuana to schedule II

Allow banks to provide checking accounts and other financial services to marijuana dispensaries

Allow Veterans Administration physicians to recommend medical marijuana to veterans

Eliminate barriers to medical marijuana research

xpansion, and
tates Act (CARERS)
Tetrahydrocannabinol (THC)

Tetrahydrocannabivarin (THCV)

Cannabinadiolic acid (CBDA)

Cannabinol ( CBN)

Cannabidiol (CBD)

Tetrahydrocannabinol acid (THCA)

Cannabidivarine (CBDV)

Cannabigerol (CBG)

Cannabichromene (CBC)

At a minimum the concentrations for the following cannabinoids must be reported in the final brand, in it’s final form:
NYS reportable cannabinoid profile
3. Capsules for oral administration

2. Metered liquid or oil preparations for vaporization

1. Liquid or oil preparations for oromucosal, sublingual, or per tube

July 2014 Governor Cuomo approved the Compassionate Care Act in NYS

July 2015 Five (5) Registered Organizations (RO) allowed to grow and manufacture medical marijuana

Each RO allowed to provide product to 4 Dispensing Facilities (20 in total across NYS)

Each RO can only produce 5 strains (mandatory: 1 strain low THC and high CBD (e.g. 1:20) and 1 strain of equal THC and CBD)

Each brand shall have a maximum of 10mg total THC per dose

Anticipated start date: January 5, 2016. Actually started January 7, 2016

Three forms:

NYS Regulation
Why did we get involved with cannabis as medicine?
Presumptions of Marijuana
Reality of Cannabis

Visit us on Facebook at:
Medical Cannabis Connection of NY

Psychoactive Cannabinoids Non-psychoactive Cannabinoids
Any other cannabinoid component at >0.1%
There are 62 counties in New York and only 13 have a dispensing facility.

Not all dispensing facilites are open.

Dispensing Facilities do not have a full product line per regulations.

The City of Buffalo, the 2nd largest city in New York State does not have a Dispensing Facility or Registered Organization.

Each Registered Organization is producing different products.
Patient Safety Organizations
Collaboration with providers, patients, dispensing facilities and academic institutions to provide safety and monitoring

Additional assistance with applications, registration, and follow up care

Optimizing outcomes

Added security with drug interaction monitoring

Data collection


Amyotrophic lateral sclerosis (ALS)

Parkinson’s disease

Multiple sclerosis

Damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity


Inflammatory bowel disease


Huntington’s disease

Any condition added by the Commissioner of Health

NYS Approved Severe Debilitating or Life-threatening Conditions For Use
Full transcript